Table 5.
Shock Details
| Therapy zone | Ultra‐Conservative | Control |
|---|---|---|
| Appropriate shocks | ||
| VT/VT‐1 | 0 | 1 |
| Median TCL, ms | NA | 380 |
| FVT/VT‐2 | 2 | 1 |
| Median TCL, ms | 310 | 300 |
| VF | 4 | 9 |
| Median TCL, ms | 235 | 265 |
| ATP delivered (% of events) | 5 (83%) | 2 (18%) |
| Acceleration w/ATP | 1 | 0 |
| Symptomatic | 0 | 0 |
| Inappropriate shocks | ||
| VT/VT‐1 | 0 | 0 |
| Median TCL, ms | NA | NA |
| FVT/VT‐2 | 3 | 0 |
| Median TCL, ms | 310 | NA |
| VF | 2 | 1 |
| Median TCL, ms | 285 | 280 |
| ATP delivered (% of events) | 2 (40%) | 1 (100%) |
| Acceleration w/ATP | 0 | 0 |
| Symptomatic | 0 | 0 |
Values are presented as the number of patients experiencing a shock within each therapy zone. Acceleration refers to acceleration of a tachycardia with ATP, ie, a decrease in average tachycardia cycle length of 10 ms. ATP indicates anti‐tachycardia pacing; TCL, tachycardia cycle length; VF, ventricular fibrillation; VT, ventricular tachycardia.